Crystalline edg-2 receptor antagonist and methods of making
AssigneeSanofi
InventorsJosef PERNERSTORFER, William ROCCO, Jason BRITTAIN
Life of this patent
Estimating the term…
Abstract
Described herein are crystalline forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid and methods of making the same. Such forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid are useful in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with an EDG-2 receptor antagonist compound.
Claims27
Crystalline Form 1 of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I), characterized as having an X-ray powder diffraction (XRPD) pattern with peaks at 5.2±0.2° 2-Theta, 9.0±0.2° 2-Theta, 14.4±0.2° 2-Theta, and 17.7±0.2° 2-Theta, as measured using Cu (Kα) radiation.
Crystalline Form 1 of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I), characterized as having an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 1, as measured using Cu (Kα) radiation.
Amorphous phase of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I) characterized as having:
- an X-ray powder diffraction (XRPD) pattern showing a lack of crystallinity, and a Solid State 13Carbon Nuclear Magnetic Resonance (ssNMR) spectrum substantially the same as shown in FIG. 16.
A pharmaceutical composition comprising crystalline Form 1 of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid (Compound I), and at least one pharmaceutically acceptable excipient;
- wherein crystalline Form 1 of Compound I is characterized as having an X-ray powder diffraction (XRPD) pattern with peaks at 5.2±0.2° 2-Theta, 9.0±0.2° 2-Theta, 14.4±0.2° 2-Theta, and 17.7±0.2° 2-Theta, as measured using Cu (Kα) radiation;
- and
- wherein the pharmaceutical composition is in the form of a solid form pharmaceutical composition.
Dependencies are inferred from the claim text.